Summary
A randomized trial of surgical adjuvant chemoimmunotherapy was conducted in patients who had undergone palliative gastrectomy for previously untreated advanced stomach cancer. First, all patients received the same induction chemoimmunotherapy with MFC (mitomycin C, 5-fluorouracil, and cytosine arabinoside) plus OK-432 for 6 weeks after surgery. The patients were then randomized to receive either chemoimmunotherapy with MFC plus OK-432 (group A) or immunotherapy with OK-432 alone (group B) for maintenance. The survival rate of patients was significantly higher in group B (44 cases) than in group A (39 cases) during the first 9 months after the start of induction therapy (P<0.05). A further division of patients in terms of carcinoma histology revealed a difference in survival rate only in patients with an undifferentiated histology (poorly differentiated adenocarcinoma and signet-ring cell carcinoma), and not in those with a differentiated histology (papillary, tubular, and mucinous adenocarcinomas). These results indicate that simple immunotherapy with OK-432 is better for maintenance than chemoimmunotherapy involving MFC, particularly in patients with undifferentiated gastric carcinomas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chugai Pharmaceutical Co. Ltd (1979) Host defense stimulator, antitumor Str. pyogenes preparation, Picibanil (OK-432). Chugal Shuppan, Tokyo
Cox DR (1972) Regression models and life tables. J R Stat Soc [B] 34: 187–220
Edynak EM, Oishi N, Gordon BL, Deich A (1977) Immunotherapy of carcinoma of the stomach: a status report. Hawaii Med J 36: 71–73
Ishii Y, Yamaoka H, Toh K, Kikuchi K (1976) Inhibition of tumor growth in vivo and in vitro by macrophages from rats treated with a streptococcal preparation, OK-432. Gann 67: 115–119
Japanese Research Society for Gastric Cancer (1974) The general rules for the gastric cancer study in surgery and pathology, 9th edn. Kimbara Shuppan, Tokyo
Kai S, Tanaka J, Nomoto K, Torisu M (1979) Studies on the immunopotentiating effects of a streptococcal preparation, OK-432. I. Enhancement of T cell-mediated immune responses of mice. Clin Exp Immunol 37: 98–105
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Kataoka T, Ohashi F, Sakurai Y (1979) Immunotherapeutic response of concanavalin A-bound L1210 vaccine enhanced by a streptococcal immunopotentiator, OK-432. Cancer Res 39: 2807–2810
Lauren P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histoclinical classification. Acta Pathol Microbiol Scand 64: 31–49
Ota K, Kurita S, Nishimura M, Ogawa M, Kamei Y, Imai K, Ariyoshi Y, Kataoka K, Murakami M, Oyama A, Hoshino A, Amo H, Kato T (1972) Combination therapy with mitomycin C (NSC-26980), 5-fluorouracil (NSC-19893), and cytosine arabinoside (NSC-63878) for advanced cancer in man. Cancer Chemother Rep [1] 56: 373–385
Sakurai Y, Tsukagoshi S, Satoh H, Akiba T, Suzuki S, Takagaki Y (1972) Tumor-inhibitory effect of a streptococcal preparation (NSC-B116209). Cancer Chemother Rep [1] 56: 9–17
Tokai Cooperative Study Group for Ajuvant Immunochemotherapy of the Stomach Cancer (1976) Study on adjuvant immunochemotherapy of the stomach cancer. Gran-to-Kagakurycho 3: 715–721
Tsukamoto K, Gaitan-Yanguas M (1973) A system for registration and classification of stomach cancer for WHO international reference center. Jpn J Clin Oncol 12: 117–128
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1980) Suppression of Friend leukemia virus by Bacillus Calmette-Guérin and a streptococcal preparation, OK-432. Int J Cancer 25: 131–136
Uchida A, Hoshino T (1980) Clinical studies on cell-mediated immunity in patients with malignant disease. I. Effect of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsiveness in vitro. Cancer 45: 476–483
Author information
Authors and Affiliations
Additional information
Chairman of the Study Group: K. Ota
Rights and permissions
About this article
Cite this article
Yasue, M., Murakami, M., Nakazato, H. et al. A controlled study of maintenance chemoimmunotherapy vs immunotherapy alone immediately following palliative gastrectomy and induction chemoimmunotherapy for advanced gastric cancer. Cancer Chemother. Pharmacol. 7, 5–10 (1981). https://doi.org/10.1007/BF00258205
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00258205